Roche Diagnostics U.S. Media Relations
BASEL, February 23, 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer.
A brain tumor is formed when there is an abnormal growth of cells in the brain. There are two main types of cells in the brain: neurons, the communicators of the nervous system, and glial cells, which support and protect neurons and maintain the body’s natural state of balance. Gliomas, brain tumors that develop from glial cells, are the most prevalent type of malignant brain tumors in adults.1
Gliomas that have mutations in the IDH1 and ATRX genes are biologically distinct from tumors that do not carry these mutations. Knowing a patient’s IDH1 and ATRX mutation status enables clinicians to provide personalized care to patients based on their specific tumor classification, including a more informed prognosis, the selection of targeted therapies and inclusion in clinical trials.2
Time is critical for patients fighting brain cancer. Patients diagnosed with glioblastoma, the most common brain cancer in adults, have an average survival rate of less than one year. Having an understanding of a glioma patient's mutation status will enable clinicians to quickly determine the optimum treatment path for that patient and help predict therapeutic outcomes.
Immunohistochemistry is recommended by all major glioma practice guidelines for determining IDH1 R132H and ATRX mutation status.3-5 When compared to sequencing, identification of IDH1 R132H mutations via immunohistochemistry has been shown to be more accurate, rapid, accessible and cost-effective.6 The IDH1 assay can also detect the IDH1 R132H mutation in acute myeloid leukemia (AML).
Roche’s IDH1 and ATRX assays are optimized and fully automated on the BenchMark series of instruments. The two tests are now available in the U.S. They will likely be available in other non-CE markets later this year and in countries that accept the CE mark in 2024.
Roche’s IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody can detect the IDH1 R132H mutation in adult-type gliomas and in acute myeloid leukemia (AML). When present, IDH1 R132H is associated with a relatively favorable prognosis and is important in patient stratification for clinical trials.2 IDH1 R132H immunohistochemistry is recommended by all major glioma clinical practice guidelines as the initial IDH testing modality.3-5 Roche’s ATRX Rabbit Polyclonal Antibody detects a mutation in the ATRX gene, providing significant diagnostic and prognostic information to clinicians. ATRX testing is considered “desirable” by the World Health Organization for IDH-mutant gliomas.3
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.